Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Pediatr Infect Dis J. Author manuscript; available in PMC 2012 December 2.
Published in final edited form as:
PMCID: PMC3511890

HIV and Hepatitis B Co-infection Among Perinatally HIV-infected Thai Adolescents



The study aimed to determine prevalence of hepatitis B virus (HBV) co-infection and HBV antibody in perinatally HIV-infected adolescents. A secondary objective was to describe the clinical characteristics of adolescents with chronic HBV- and HIV co-infection.


A multi-center cross sectional study of HIV-infected adolescents aged between 12–25 years


Hepatitis B surface antigen (HBsAg), surface antibody(anti-HBs) and core antibody(anti-HBc) were measured. Co-infection was defined as having persistent positive HBsAg. Seroprotective antibody from immunization was defined as having anti-HBs > 10 mIU/mL with negative anti-HBc.

HBV DNA, and rtM204V/I mutation analysis (lamivudine resistance associated mutation) was performed in adolescents with chronic HBV infection.


From November 2010 to March 2011, 521 patients were enrolled. Mean (SD) of CD4 lymphocyte count was 685(324) cells/μl. Prevalence of HBV/HIV co-infected was 3.3%; 95% CI:1.9% to 5.2 %. Protective antibody against HBV was found in 18% of population, and this was significant higher among adolescents who received hepatitis B revaccination after receiving antiretroviral therapy (93% vs. 6%, p<0.01). Among adolescents with chronic HBV infection, 88% have received lamivudine; however 69% have HBV DNA > 105 copies/ml, and 75% had the rtM204V/I mutation.


The prevalence of HBV co-infection in HIV-infected Thai adolescents was 3.3%. Majority of HIV-infected adolescents had no HBV protective antibody; therefore revaccination with HBV vaccine is encouraged. A high prevalence of HBV-lamivudine resistance mutation was found, therefore HBV screening for all children prior to initiation of antiretroviral treatment should be considered to select appropriate regimen regarding both viral infections.

Keywords: HIV, adolescents, hepatitis B, co-infection


An estimated 350 million persons worldwide are chronically infected with hepatitis B (HBV) [1]. Among HIV-infected populations, HBV is more prevalent due to overlapping transmission routes, e.g., perinatal, percutaneously contact with body fluid, and sexual exposure. The risk of developing chronic HBV infection after acute exposure ranges from 90% in newborns of HBeAg-positive mothers, to 25%-30% in infants and children under 5 years, and to less than 5% in adults [2].

HIV infection greatly affects the clinical course of hepatitis B virus infection [3]. Patients with co-infection have higher HBV DNA levels, a decreased likelihood of HBV clearance which leads to a higher chance of developing chronic HBV infection ranging from 10–15% [4], and higher rates of HBV-associated liver disease [5]. Several reverse transcriptase inhibitors, for example lamivudine and tenofovir, have activity against both HIV and HBV, making therapeutic decisions more complicated. Treating HIV infection without knowing patients’ hepatitis serostatus might lead to selection of HBV-resistant mutants and vice versa [6].

The prevalence of HIV-HBV co-infection among HIV-infected adults in Thailand and in Asia is reported to be in the range of 8.7%–10% [7, 8], and 4.9% among HIV-infected children in China [9]. As of 2010, the incidence of hepatitis B infection in Thailand was only 8.4 per 10,000 persons in the population due to high coverage of immunization during childhood [10]. However, there has been no routine hepatitis B screening program among HIV-infected children in Thailand. HBV-HIV co-infection becomes an important issue when HIV-infected children become adolescents since HBV can enter a period of immune activation, and risk developing HBV drug resistance if prolonged used of lamivudine monotherapy.

This study aimed to determine the prevalence of hepatitis B virus (HBV) co-infection and protective HBV antibody in perinatally HIV-infected adolescents. The secondary objective was to describe the clinical characteristics of adolescents with chronic HBV- and HIV co-infection.

Patients and Methods

A cross-sectional study was conducted at 4 sites in Thailand, namely Research Institute for Health Sciences, Chiang Mai University (RIHES-CMU), Chiang Mai, the HIV-Netherlands-Australia-Thailand Research Collaboration (HIV-NAT), Thai Red Cross AIDS Research Centre in collaboration with Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Chiangrai Prachanukroh Hospital, Chiangrai, and Srinagarind Hospital, Khon Kean. All 4 sites participate in the Therapeutics, Research, Education and AIDS Training in Asia (TREAT Asia) Pediatric Network. Data on all children receiving HIV-related medical care at the participating sites were collected. Inclusion criteria were HIV-infected children participating in TREAT Asia Pediatric HIV Observational Database (TApHOD) at specified sites, aged ≥ 12 years to 25 years. The study was approved by the research ethics committee of all sites. Written informed consent was obtained from adolescents or guardians at the time of enrollment.

Medical history was extracted from medical record or the TApHOD database. Risk of HBV infection including maternal history of HBV infection, history of blood transfusion and sexual history was assessed by interview.

Laboratory measurements

Hepatitis B serostatus was determined by serologic testing which included hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), and hepatitis core antibody (anti-HBc). HBsAg detection was performed by Microparticle Enzyme Immunoassay (MEIA), or Enzyme-linked immunosorbent assay (ELISA) test or Immunochemiluminescence (CMIA). Anti-HBs, and anti-HBc were measured using the Abbott AxSYM system (Wiesbaden, Germany), ELISA, or CMIA.

HBV-HIV Co-infection was defined as persistent positive HBsAg, resolved natural infection was defined as having both anti-HBc and anti-HBs positive, and seroprotective antibody from immunization was defined as having anti-HBs ≥ 10 mIU/mL with negative antiHBc [11]. Children with HBV-HIV co-infection had a second blood drawn to test for the presence of HBe Ag, anti-HBe, HBV DNA level and lamivudine resistance mutation. HBe Ag and anti-HBe were measured by Abbott AxSYM, Microparticle enzymatic immunoassay (MEIA) at the HIV-NAT laboratory.

HBV DNA was measured by a real-time PCR assay a with limit of detection of 100 copies/mL [12,13]. HBV genotype was determined by comparing with each complete HBV genome sequences. Phylogenetic analysis was constructed by Molecular Evolutionary Genetics Analysis (MEGA) software version 3.1 [13]. HBV Mutation Analysis assessed the presence of rtM204V/I by pinpointing the change in the YMDD motif; HBV nucleotides were translated into amino acid sequences using the translation tool provided by the ExPASy Proteomics Server (available at: [14] at the Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University. The whole genome HBV sequences obtained from this study were submitted into the GenBank database with the accession no. JN827414–JN827425. Alanine aminotransferase (ALT) was considered elevated using a cut-off >30 IU/L [15].

Statistical analysis

The prevalence of HBV-HIV co-infection, resolved natural infection, and HBV seroprotection were reported as a proportion with 95% confidence intervals. The Chi square test or Fisher’s exact and logistic regression analysis were to make comparisons between groups. All analyses were performed using the Statistical Package for Social Science version 17.0 software (SPSS Inc., Chicago, IL, USA).


From Nov 2010 to Mar 2011, 521 patients were enrolled; 227 (44%) were male; their mean age (SD) was 14.8 (2.1) years. Only 15 adolescents (3%) were born before 1992 when routine HBV immunization was not implemented in Thailand. Their mean current CD4 lymphocyte count (SD) was 685 (324) cells/μL and 86% were virologically suppressed. Two hundred and eighty one cases (54%) had either reported or documented HBV vaccination during childhood. Seventy-five of 521 (14%) had received a 3-dose HBV revaccination after immune recovery as a result of antiretroviral treatment. The median time between revaccination and blood draw for this study was 4.3 (IQR 3.7–4.5 years). Risk factors for HBV other than perinatally transmission were previous blood transfusion in 10 cases (2%), and history of engaging in sexual activity in 40 cases (8%). Hepatitis B serostatus stratified by study site is shown in Table 1. Seventeen children were HBV/HIV co-infected [3.3%; 95% CI: 1.9% to 5.2%]. A comparison of characteristics among those with and without HBV co-infection is shown in Table 2. Among 15 cases born before 1992, one case (6.7%) had positive HBsAg and one (6.7%) had resolved natural infection. Three of those who had hepatitis B revaccination after HAART had protective antibody against hepatitis B

Table 1
Hepatitis B serostatus stratified by study site
Table 2
Characteristics of HIV-infected adolescents with and without HBV co-infection

The clinical characteristics of 17 adolescents with chronic HBV infection are summarized in Table 3. Mean (SD) age and CD4 lymphocyte count were 16.3 (2.3) years and 591 (277) cells/μL. Eleven of 16 (69%) had HBV DNA > 105 copies/mL. Only 2 cases had HBV DNA < 100 copies/mL; one was currently treated with lamivudine and tenofovir. HBeAg was presented in 14/16 cases (88%) while anti-HBe was presented in only 1/16 (6%). Anti-HBc could not be detected in 5 cases. There were 6 participants (35%) with elevated ALT > 30 IU/L. Current antiretroviral drugs included lamivudine (88%) and tenofovir (12%). Resistance to lamivudine was detected in 9 of 12 cases tested (75%).

Table 3
Details of 17 adolescents with Hepatitis B and HIV co-infection

Resolved natural infection was found in 8 cases [1.5%; 95%CI: 0 to 3%]. None of them had documented or recalled a history of clinical hepatitis. Isolated core antibody (Anti-HBc) was detected in 4 cases [0.8%; 95% CI: 0 to 2%]. Ninety-six cases (18%) had protective antibody against HBV with a significantly higher proportion found among adolescents who received HBV revaccination after receiving antiretroviral therapy (93% vs. 6%, p<0.01). The characteristics of participants with and without protective antibody against hepatitis B are shown in Table 4. The group with protective antibody had higher mean age, higher CD4 lymphocyte count, and a higher proportion had been previously immunized against HBV.

Table 4
Characteristics of HIV-infected adolescents with and without protective antibody against hepatitis B


The prevalence of HBV/HIV co-infection is 3.3% in perinatally HIV-infected Thai adolescents receiving ART. Only18% of adolescents had protective antibody against hepatitis B virus. Approximately 70% of adolescents with HBV co-infection had high HBV DNA and lamivudine resistance associated mutations.

The prevalence of HBV co-infection in our study was higher than that reported among a non-HIV-infected, healthy Thai population. Data from a countrywide HBsAg seroprevalence survey conducted in 2004 showed a prevalence of 4.4% and 0.82% among those who were born before 1992 and after 1992, respectively [16]. Almost all (97%) of participants in our study were born after national universal hepatitis immunization was implemented in Thailand provides evidence that hepatitis B infection is more prevalent in HIV-positive Thai children.

The HIV-HBV co-infection prevalence in our study is lower than that reported in other Asian and African countries. A Chinese study demonstrated HBV co-infection among 4.9% of children with a median age of 7 years [9]. HBsAg seroprevalence in our study was slightly lower, while the prevalence of HBV carriers in general population was similar at around 10% [7, 8]. A study conducted in HIV-infected Nigerian children aged from 10 months to 17 years, reported the prevalence of HIV/HBV co-infection was 7.7%, while the prevalence of HBs Ag in Nigerian adults ranged from 7.5 to 44.7% [17] while studies in HIV-infected Kenyan children aged 0–12.7 years (2003) and Tanzanian children ages ranged from < 2 to > 15 years (2006) have reported positive HBsAg in 4% and 1.2%, respectively [18, 19].

Five adolescents with HBV-HIV co-infection in our cohort had negative anti-HBc, and this could probably be explained by false negative anti-HBc result, since HBV DNA was detected in 4 out of 5 of these cases. All of them were viral suppressed and in good immune status with current CD4 lymphocyte count ranged from 376–920 cells/μl.

We found isolated core antibody in 4 cases (0.8%), none had detected HBV DNA. This meant natural infection has been occurred without antibody response to protective level (negative anti-HBs when the cut-off 10 mIU/mL was used), or antibody response might have happen but subsequently waning with time. All of them were female, at ages ranged between 12.2–15.9 years which were not different from mean age of participants in this cohort. An adult HIV study in Taiwan where HBV infection was hyperendemic reported the prevalence of isolated Anti-HBc is 17.5%, with HBV DNA detectable in 8.3% of those patients. The authors suggested this might be related to old age and low CD4 lymphocyte count of the study participants [20]. A US study observed that individuals co-infected with HIV and hepatitis C virus were more likely to have isolated core antibody (anti-HBc) than HIV infected individuals without hepatitis C infection [21]; they claimed that it was associated with the severity of immune suppression. As the current CD4 lymphocyte count of our 4 cases at the time of the study ranged from 260–1327 cells/μl, it might not be the case. However, the number was too few to find out predictors for isolated core antibody.

Low hepatitis B seroprotective antibody rates (18%) in this study might be due to the primary vaccine failure or waning of immunity during the period of immunosuppression prior to antiretroviral initiation. The P1024US study, also reported that 24% of HIV-infected children receiving antiretroviral therapy were hepatitis B seropositive [22]. Revaccination of hepatitis B vaccines may therefore be needed in this population. We have previously reported that 92% of HIV-infected children with immune recovery after ART had HBV seroconversion after revaccination with a 3-dose recombinant HBV vaccine [23]. Furthermore, the protective antibody against HBV is sustainable in 71% of children on stable on antiretroviral treatment with immune recovery, three years after revaccination [24].

In our study, 75% of children had HBV-3TC associated mutations. This is in line with a previous report that 3TC monotherapy is associated with a high risk of developing the M204V resistance mutation, at a rate of approximately 20–25% per year [25,26]. In our study, the median duration of antiretroviral drug therapy was 7 years. The HBV DNA levels in our study were very high: 69% of children had> 105 copies/mL. 3TC monotherapy in children was less likely to suppress HBV DNA < 3 log10 copies/mL at week 48 compared to those who received tenofovir plus 3TC (46% versus 92%) [27]. Thus, we propose that HIV adolescents with HBV co-infection should receive combination therapy with tenofovir plus 3TC similar to that recommended in the adult population [28].

There are some study limitations to be addressed. First, we did not have a history of maternal HBV status and information on access to hepatitis B immunoglobulin which are the main factors influencing HBV transmission risk. Second, we conducted our study at tertiary care hospitals which may represent a group of participants with different characteristics than those who received HIV care at local hospital. However, we do not anticipate any difference in HBV prevalence rates at local hospitals, since all our cases were asymptomatic.

A strength of this study comes from the systematic screening for hepatitis B co-infection in perinatally HIV-infected adolescents conducted in four sites, which represent adolescents surviving with HIV in different parts of the country. In addition, we confirmed chronic HBV infection by testing for HBV DNA.

In conclusion, the prevalence of HBV co-infection in HIV-infected Thai adolescents is higher than general population in the era of routine HBV immunization. The prevalence of HBV seroprotection is low despite childhood vaccination, and 80% of HIV-infected adolescents on ART remain at risk for HBV infection. Thus, revaccination with HBV vaccine should be encouraged in this population.


-Grant from TREAT Asia Supplemental Funding, the TREAT Asia Pediatric HIV Observational Database is an initiative of TREAT Asia, a program of amfAR, The Foundation for AIDS Research, with support from the U.S. National Institutes of Health’s National Institute of Allergy and Infectious Diseases, Eunice Kennedy Shriver National Institute of Child Health and Human Development, and National Cancer Institute as part of the International Epidemiologic Databases to Evaluate AIDS (IeDEA; U01AI069907), and the Austrian AIDS Life Association.

-The National Research University Project of Commission of Higher Education and the Ratchadapiseksomphot Endowment Fund (HR 1161A), (Puthanakit T, Pooworawan Y)

-Integrated Research to Expand the Capacity for Diagnosis, Management, and Prevention of AIDS/HIV, Sexual transmitted diseases (STI) and AIDS related Opportunistic Infections: A Model development for Resource Limited Countries (Aurpibul L)

-We would like to thank participants and families who participated in the study. We would like to thank Stephen Kerr, Ph.D. for his help on preparing the English manuscript.


1. World Health Organization. [Accessed Mar 25, 2011.];Hepatitis B fact sheet. Available at:
2. McMahon BJ, Alward WL, Hall DB, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis. 1985;151:599–603. [PubMed]
3. Piroth L, Sène D, Pol S, et al. Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY) AIDS. 2007;21:1323–1331. [PubMed]
4. McGovern BH. The epidemiology, natural history and prevention of hepatitis B: implications of HIV co-infection. Antivir Ther. 2007;12:H3–H13. [PubMed]
5. Soriano V, Puoti M, Bonacini M, et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS. 2005;19:221–240. [PubMed]
6. Sulkowski MS. Management of hepatic complications in HIV-infected persons. J Infect Dis. 2008;197:S279–S293. [PubMed]
7. Zhou J, Dore GJ, Zhang F, Lim PL, Chen YM. Hepatitis B and C virus co-infection in The TREAT Asia HIV Observational Database. J Gastroenterol Hepatol. 2007;22:1510–1518. [PubMed]
8. Law WP, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, et al. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS. 2004;18:1169–1177. [PubMed]
9. Zhou S, Zhao Y, He Y, et al. Hepatitis B and hepatitis C seroprevalence in children receiving antiretroviral therapy for human immunodeficiency virus-1 infection in China, 2005–2009. J Acquir Immune Defic Syndr. 2010;54:191–196. [PMC free article] [PubMed]
10. Annual Epidemiological Surveillance Report 2010. Bureau of Epidemiology; [Accessed Sep8, 2011.]. Available at
11. Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC. What level of hepatitis B antibody is protective? J Infect Dis. 1999;179:489–492. [PubMed]
12. Payungporn S, Tangkijvanich P, Jantaradsamee P, Theamboonlers A, Poovorawan Y. Simultaneous quantitation and genotyping of hepatitis B by real- time PCR and melting curve analysis. J Virol Methods. 2004;120:131–140. [PubMed]
13. Sa-nguanmoo P, Tangkijvanich P, Thawornsuk N, et al. Molecular epidemiological study of hepatitis B virus among migrant workers from Cambodia, Laos, and Myanmar to Thailand. J Med Virol. 2010;82:1341–1349. [PubMed]
14. Sa-nguanmoo P, Tangkijvanich P, Payungporn S, et al. Dynamics of HBV DNA levels, HBV mutations and biochemical parameters during antiviral therapy in a patient with HBeAg-negative chronic hepatitis B. Asian Pac J Allergy Immunol. 2007;25:183–188. [PubMed]
15. Brook G, Main J, Nelson M, et al. BHIVA Viral Hepatitis Working Group. British HIV Association guidelines for the management of co-infection with HIV-1 and hepatitis B or C virus. HIV Med. 2010;11:1–30. [PubMed]
16. Chongsrisawat V, Yoocharoen P, Theamboonlers A, et al. Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization. Trop Med Int Health. 2006;11:1496–1502. [PubMed]
17. Sadoh AE, Sadoh WE, Iduoriyekemwen NJ. HIV co-infection with hepatitis B and C viruses among Nigerian children in an antiretroviral treatment programme. SAJCH. 2011;5:7–10.
18. Rana C, Gareth R, Dimitra B, et al. Viral co-infection among Children Infected with HIV Type 1. Clin Infect Dis. 2003;36:922–924. [PubMed]
19. Telatela S, Matee M, Munubhi EK. Seroprevalence of hepatitis B and C viral co-infections among children infected with human immunodeficiency virus attending the paediatric HIV care and treatment center at Muhimbili National Hospital in Dar-es-Salaam, Tanzania. BMC Public Health. 2007;7:338. [PMC free article] [PubMed]
20. Sun HY, Lee HC, Liu CE, et al. Factors associated with isolated anti-hepatitis B core antibody in HIV-positive patients: impact of compromised immunity. J Viral Hepat. 2010;17:578–587. [PubMed]
21. Gandhi RT, Wurcel A, Lee H, et al. Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1 infected individuals. Clin Infect Dis. 2003;36:1602–1605. [PubMed]
22. Abzug MJ, Warshaw M, Rosenblatt HM, et al. International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1024 and P1061s Protocol Teams. Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis. 2009;200:935–946. [PMC free article] [PubMed]
23. Lao-araya M, Puthanakit T, Aurpibul L, Sirisanthana T, Sirisanthana V. Antibody response to hepatitis B re-vaccination in HIV-infected children with immune recovery on highly active antiretroviral therapy. Vaccine. 2007;25:5324–5329. [PubMed]
24. Aurpibul L, Sujaridruk T, Lao-araya M, Puthanakit T, Sirisanthana T, Sirisanthana V. Persistence of Protective Antibody to Hepatitis B. Japanese Encephalitis, Measles, Mumps, and Rubella up to 3 years After Revaccination in HIV-infected Children with Immune Recovery [Abstract 880]. 17th Conference on Retroviruses & Opportunistic Infections; San Francisco, CA. February 16 to19, 2010.
25. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology. 1999;30:1302–6. [PubMed]
26. Thio CL. Virology and clinical sequelae of drug-resistant HBV in HIV-HBV co-infected patients on HAART. Antivir Ther. 2010;15:487–491. [PMC free article] [PubMed]
27. Matthews GV, Avihingsanon A, Lewin SR, et al. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand. Hepatology. 2008;48:1062–1069. [PubMed]
28. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; Jan 10, 2011. pp. 1–166. Available at: